96 Tests PN: B111414

Components:

45x Ab-conjugated beads (S4P8 - human IL-18BP/IL-18BPa/IL-18 Binding Protein-bead). PN: B111414A. One vial containing 100 µL of anti-human IL-18BP/IL-18BPa/IL-18 Binding Protein conjugated to AimPlex Bead S4P8.

25x Biotin-detection Ab (human IL-18BP/IL-18BPa/IL-18 Binding Protein Biotin-dAb). PN: B111414B. One vial containing 100 µL of biotinylated anti-human IL-18BP/IL-18BPa/IL-18 Binding Protein.

Lyophilized Standard - Human IL-18BP/IL-18BPa/IL-18 Binding Protein. PN: B111414S. One vial containing lyophilized IL-18BP/IL-18BPa/IL-18 Binding Protein.

Storage:  2-8 C in the dark.

Important: Sodium azide forms explosive compounds with heavy metals. These products contain <0.05% (w/w) azide which with repeated contact with lead and copper commonly found in plumbing drains may result in the buildup of shock sensitive compounds. Dispose in accordance with regulations from your institute.

Application: Optimal antibody pair and antigen standard for assaying human IL-18BP/IL-18BPa/IL-18 Binding Protein. To be used in conjunction with the AimPlex NR Basic Kit (PN: P100001) and a diluent kit. Refer to the AimPlex Multiplex Immunoassay User Manual and kit inserts for the assay procedure.

For Research Use Only.  Not for use in diagnostic procedures.

Assay Specifications:

  • Sample types: Cell culture supernatant, serum, plasma, bodily fluid and tissue/cell lysate

  • Sensitivity (LOD): < 100 pg/mL

  • Quantitation range:

  • LLOQ: < 200 pg/mL

  • ULOQ: > 50,000 pg/mL

  • Standard dose recovery: 70-130%

  • Intra-assay CV: < 10%

  • Inter-assay CV: < 20%

  • Sample volume: 15 µL/test

Description:

IL-18BP/IL-18BPa/IL-18 Binding Protein (Accession AAD17190) binds to IL-18, preventing it from interacting with the IL-18 receptor. This prevents the downstream signaling pathways that IL-18 would activate. IL-18BP's ability to modulate IL-18 activity suggests a potential involvement in various inflammatory and autoimmune disorders. IL-18BP is currently under investigation as a possible therapeutic target for conditions characterized by excessive IL-18 activity, including certain autoimmune and inflammatory diseases.

References:  

1.    Fujita K, et al. Immunomodulatory IL-18 binding protein is produced by prostate cancer cells and its levels in urine and serum correlate with tumor status. Int J Cancer. 2011 Jul 15;129(2):424-32. doi: 10.1002/ijc.25705.

2.    Dinarello CA, et al. Interleukin-18 and IL-18 binding protein. Front Immunol. 2013 Oct 8;4:289. doi: 10.3389/fimmu.2013.00289.